Compare · NVO vs PCVX
NVO vs PCVX
Side-by-side comparison of Novo Nordisk A/S (NVO) and Vaxcyte Inc. (PCVX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NVO and PCVX operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $196.77B, about 27.9x PCVX ($7.06B).
- Over the past year, NVO is down 39.5% and PCVX is up 39.5% - PCVX leads by 79.0 points.
- NVO has been more active in the news (11 items in the past 4 weeks vs 2 for PCVX).
- NVO has more recent analyst coverage (25 ratings vs 11 for PCVX).
- Company
- Novo Nordisk A/S
- Vaxcyte Inc.
- Price
- $44.05-3.39%
- $48.86-4.99%
- Market cap
- $196.77B
- $7.06B
- 1M return
- +4.41%
- -14.70%
- 1Y return
- -39.50%
- +39.48%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2020
- News (4w)
- 11
- 2
- Recent ratings
- 25
- 11
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Vaxcyte Inc.
Vaxcyte, Inc., a preclinical-stage biotechnology vaccine company, develops novel vaccines to prevent or treat infectious diseases worldwide. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine. The company also develops VAX-XP to protect against emerging strains and address antibiotic resistance; VAX-A1, a conjugate vaccine candidate designed to treat Group A Strep; and VAX-PG, a novel protein vaccine candidate targeting Porphyromonas gingivalis. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in Foster City, California.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form SD filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- The $59B Quiet Shift Reshaping How Patients Access Care
- Peptide Wellness Market Could Near $300 Billion as Consumer Demand Accelerates
Latest PCVX
- Amendment: SEC Form SCHEDULE 13G/A filed by Vaxcyte Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by Vaxcyte Inc.
- SEC Form 10-Q filed by Vaxcyte Inc.
- Vaxcyte Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Vaxcyte Reports First Quarter 2026 Financial Results and Provides Business Update
- Amendment: SEC Form SCHEDULE 13G/A filed by Vaxcyte Inc.
- CHIEF OPERATING OFFICER Wassil Jim sold $127,870 worth of shares (2,250 units at $56.83) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 160,744 units (SEC Form 4)
- SEC Form DEFA14A filed by Vaxcyte Inc.
- SEC Form DEF 14A filed by Vaxcyte Inc.
- SEC Form 4 filed by Cowan Elvia